Principal Financial Group Inc. Sells 213,538 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Principal Financial Group Inc. decreased its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 88.7% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 27,275 shares of the biopharmaceutical company’s stock after selling 213,538 shares during the period. Principal Financial Group Inc.’s holdings in Amicus Therapeutics were worth $291,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. American International Group Inc. lifted its position in Amicus Therapeutics by 1.3% during the first quarter. American International Group Inc. now owns 143,034 shares of the biopharmaceutical company’s stock worth $1,685,000 after acquiring an additional 1,785 shares during the last quarter. CANADA LIFE ASSURANCE Co lifted its holdings in Amicus Therapeutics by 7.8% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 100,538 shares of the biopharmaceutical company’s stock worth $1,183,000 after purchasing an additional 7,304 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Amicus Therapeutics by 0.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,389,361 shares of the biopharmaceutical company’s stock valued at $16,368,000 after purchasing an additional 12,003 shares during the period. Silvercrest Asset Management Group LLC increased its position in Amicus Therapeutics by 4.5% during the 1st quarter. Silvercrest Asset Management Group LLC now owns 374,958 shares of the biopharmaceutical company’s stock worth $4,417,000 after buying an additional 16,033 shares during the period. Finally, Bayesian Capital Management LP acquired a new stake in shares of Amicus Therapeutics during the first quarter worth $591,000.

Insider Transactions at Amicus Therapeutics

In related news, CEO Bradley L. Campbell sold 7,500 shares of the business’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $11.71, for a total transaction of $87,825.00. Following the sale, the chief executive officer now owns 886,654 shares in the company, valued at $10,382,718.34. The trade was a 0.84 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Over the last ninety days, insiders sold 30,401 shares of company stock worth $352,038. Corporate insiders own 2.20% of the company’s stock.

Amicus Therapeutics Trading Up 0.6 %

Shares of Amicus Therapeutics stock opened at $9.72 on Tuesday. The firm’s 50 day moving average is $10.80 and its 200 day moving average is $10.59. The firm has a market capitalization of $2.90 billion, a PE ratio of -28.59 and a beta of 0.68. Amicus Therapeutics, Inc. has a 1 year low of $9.02 and a 1 year high of $14.57. The company has a current ratio of 3.15, a quick ratio of 2.42 and a debt-to-equity ratio of 2.18.

Analyst Ratings Changes

FOLD has been the topic of a number of recent research reports. Jefferies Financial Group started coverage on shares of Amicus Therapeutics in a research report on Friday, September 6th. They set a “buy” rating and a $18.00 price target on the stock. Needham & Company LLC reiterated a “hold” rating on shares of Amicus Therapeutics in a research note on Thursday, November 7th. Cantor Fitzgerald raised their price objective on Amicus Therapeutics from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Guggenheim increased their target price on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Finally, JPMorgan Chase & Co. boosted their price target on Amicus Therapeutics from $16.00 to $17.00 and gave the company an “overweight” rating in a research note on Tuesday, November 12th. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.63.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.